Seyltx is developing oral therapies aimed at treating refractory chronic cough, a condition that originates in the brain and lacks effective treatments. Their lead program targets a first‑in‑class solution, while a broader pipeline advances multiple clinical‑stage and preclinical compounds toward addressing chronic cough and related respiratory disorders. The company focuses on translating neuroscience insights into novel drug candidates for patients with persistent cough symptoms.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with refractory chronic cough have persistent coughing that does not respond to existing treatments, leading to reduced quality of life and limited therapeutic options.
Solution
Seyltx is developing oral small‑molecule therapies that modulate the neural pathways in the brain responsible for triggering chronic cough. By targeting central cough reflex mechanisms, the compounds aim to reduce cough frequency and severity without the need for inhaled or injectable drugs. The lead program is positioned as a potential first‑in‑class, best‑in‑class oral option for patients who have not benefited from current therapies. Seyltx’s pipeline includes additional clinical‑stage and preclinical candidates that explore complementary mechanisms within the same neural network, providing a diversified approach to chronic cough treatment.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking novel, centrally acting treatments for patients with refractory chronic cough.
Features
- Oral formulation designed for convenient, daily dosing
- Central nervous system target that directly modulates cough reflex pathways
- Lead candidate positioned as first‑in‑class oral therapy for refractory chronic cough
- Multiple pipeline compounds at clinical and preclinical stages expanding mechanism coverage
- Designed to address unmet patient needs where existing peripheral or symptomatic treatments fail